Biomea Fusion Announces New Board Member
Biomea Fusion, Inc. (NASDAQ: BMEA), a clinical-stage company specializing in diabetes and obesity medications, is pleased to announce the addition of Julianne Averill to its Board of Directors. This appointment is effective immediately, following the resignation of Bihua Chen, who served on the Board for over four years.
About Julianne Averill
Julianne Averill joins Biomea with an impressive background in finance and strategy, boasting more than twenty years of experience in the life sciences and digital health sectors. As Managing Director at Danforth Advisors, she is responsible for driving business growth and providing strategic financial insights to biopharma companies at various stages of development.
Expertise in Healthcare Solutions
Her extensive skills encompass a variety of areas including capital markets, mergers and acquisitions, and operational scaling. Averill's impressive portfolio includes involvement in transactions valued at over $10 billion, which will greatly benefit Biomea as it seeks to innovate and expand its healthcare solutions for diabetes and obesity management.
Vision for Biomea Fusion
With a strong commitment to enhancing patient care through innovative treatments, Biomea is well-positioned to leverage Averill’s experience. Mick Hitchcock, the Interim CEO of Biomea, expressed excitement regarding Averill's appointment, stating that her leadership will significantly advance Biomea's mission to transform the landscape of diabetes and obesity care.
Her Educational Background
Julianne Averill holds a B.S. in Business Administration and an M.S. in Accountancy from California State University. She is a Certified Public Accountant in California, certified by the Society of Human Resource Management, and has earned a Directorship Certification from the National Association of Corporate Directors.
About Biomea Fusion, Inc.
Biomea Fusion is dedicated to developing innovative oral medications aimed at improving the quality of life for individuals suffering from diabetes, obesity, and related metabolic disorders. The company’s pipeline includes promising candidates like icovamenib and BMF-650, both designed with the goal of significantly enhancing patient outcomes and addressing urgent healthcare needs.
Stay Connected
For more information about Biomea Fusion and its initiatives, visit their official website. You can also follow them on LinkedIn, Twitter, and Facebook to stay updated on the latest news and developments.
Contact Information
Contact: Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
Email: IR@biomeafusion.com
Frequently Asked Questions
What does Biomea Fusion specialize in?
Biomea Fusion focuses on developing innovative treatments for diabetes and obesity through oral medications.
Who is Julianne Averill?
Julianne Averill is the newly appointed member of the Board of Directors at Biomea Fusion, bringing extensive experience in finance and strategic growth.
What is Julianne Averill's role at Danforth Advisors?
She serves as Managing Director, where she drives business growth and acts as an interim CFO for biopharma companies.
What qualifications does Julianne Averill have?
She holds a B.S. and M.S. from California State University, is a licensed CPA, and has multiple certifications in governance and corporate leadership.
How can I learn more about Biomea Fusion?
You can visit Biomea Fusion's official website and follow them on social media platforms for the latest updates.
